Market Overview:
The global sterile dry powder active pharmaceutical ingredient (API) market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for sterile dry powder APIs for various applications such as oncology, anti-diabetic, cardiovascular, and musculoskeletal diseases. In addition, the growing demand for biosimilars is also contributing to the growth of this market. North America dominates the global sterile dry powder API market followed by Europe and Asia Pacific.
 Industry Outlook.svg)
Product Definition:
A sterile dry powder active pharmaceutical ingredient (API) is an API that is in a dry form and does not contain any water. The importance of a sterile dry powder API is that it can be stored and transported without the need for refrigeration or special handling.
Chemosynthesis Drug:
Chemosynthesis drug is a type of medication that helps in the recovery from diseases by increasing the body's ability to produce chemicals needed for its functioning. Chemosynthesis API refers to any chemical or group of chemicals which play an important role in disease treatment and/or diagnosis. These are used as active pharmaceutical ingredients (APIs) during the production of sterile, dry-grade powder Active Pharmaceutical Ingredients (APIs).
Biological:
Biological and its usage in sterile dry powder active pharmaceutical ingredient (API) market is a complex process. Biological drug substance is the pure form of an active pharmaceutical ingredient used as a raw material for manufacturing drugs. It consists of proteins, peptides, nucleic acids like DNA & RNA along with some small molecules such as hormones & enzymes which are very effective to treat certain diseases but they have their own side effects.
Application Insights:
On the basis of application, the global sterile dry powder API market is segmented into oncology, anti-diabetic, cardiovascular, musculoskeletal and other diseases. The others segment includes neurology disorders and infectious diseases. Sterile powder for use in anti-infective drugs is anticipated to be the fastest growing application over the forecast period owing to its ability to prevent microbial infection during preparation and administration of pharmaceutical products.
The increasing prevalence of diabetes has led to an increased demand for innovative antidiabetic therapies that are both effective and user-friendly. This has resulted in a significant increase in research & development activities pertaining with antidiabetes applications which is expected fuel growth over the forecast period. Moreover, rising awareness about preclinical safety studies regarding potential new drug candidates prior to clinical trials being conducted further fuels growth prospects for this segment during future years spanning from 2018 through 2030 ADP).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, high R&D investments by companies, and increasing focus on product launches. In addition, growing adoption of new technologies for manufacturing products is expected to drive growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure and improving economic conditions in emerging countries such as China and India. Furthermore, an increase in chronic diseases prevalence rates coupled with rise in consumer awareness about various treatment options will boost demand further over coming years. ‘’ markstoc Marks & Spencer plc; ‘’ markdown Markdowns clothing group Inc.
Growth Factors:
- Increasing demand for sterile dry powder API in the pharmaceutical industry due to its benefits over traditional liquid APIs.
- Growing research and development activities for new drug discovery and development by pharmaceutical companies.
- Rising number of approvals for novel drugs by regulatory authorities across the globe, which is expected to fuel the demand for sterile dry powder API in the coming years.
- Technological advancements in manufacturing processes of sterile dry powder API that would help reduce production costs and boost market growth prospects over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Research Report
By Type
Chemosynthesis Drug, Biological
By Application
Oncology, Anti-Diabetic, Cardiovascular, Musculoskeletal, Others
By Companies
Dr. Reddy's Laboratories, Lonza Group, Sandoz International GmbH, Pfizer, Inc., Aurobindo Pharma Limited, Corden Pharma GmbH, Sun Pharmaceutical Industries Ltd, Sanofi SA, Dalton Pharma Services, Teva Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
153
Number of Tables & Figures
108
Customization Available
Yes, the report can be customized as per your need.
Global Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Report Segments:
The global Sterile Dry Powder Active Pharmaceutical Ingredient (API) market is segmented on the basis of:
Types
Chemosynthesis Drug, Biological
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Anti-Diabetic, Cardiovascular, Musculoskeletal, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Dr. Reddy's Laboratories
- Lonza Group
- Sandoz International GmbH
- Pfizer, Inc.
- Aurobindo Pharma Limited
- Corden Pharma GmbH
- Sun Pharmaceutical Industries Ltd
- Sanofi SA
- Dalton Pharma Services
- Teva Pharmaceutical Industries Ltd
- Dr. Reddy's Laboratories
 Market Overview.svg)
Highlights of The Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemosynthesis Drug
- Biological
- By Application:
- Oncology
- Anti-Diabetic
- Cardiovascular
- Musculoskeletal
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A sterile dry powder API is a pharmaceutical ingredient that is made up of small, discrete particles that are not water soluble. These particles are suspended in an inert carrier and typically used as a means of delivering medication to the body. Sterile dry powder APIs can be administered by injection, inhalation, or oral ingestion.
Some of the major players in the sterile dry powder active pharmaceutical ingredient (api) market are Dr. Reddy's Laboratories, Lonza Group, Sandoz International GmbH, Pfizer, Inc., Aurobindo Pharma Limited, Corden Pharma GmbH, Sun Pharmaceutical Industries Ltd, Sanofi SA, Dalton Pharma Services, Teva Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories.
The sterile dry powder active pharmaceutical ingredient (api) market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size & Forecast, 2018-2028
4.5.1 Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size and Y-o-Y Growth
4.5.2 Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Absolute $ Opportunity
Chapter 5 Global Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Type
5.2.1 Chemosynthesis Drug
5.2.2 Biological
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Applications
6.2.1 Oncology
6.2.2 Anti-Diabetic
6.2.3 Cardiovascular
6.2.4 Musculoskeletal
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Sterile Dry Powder Active Pharmaceutical Ingredient (API) Analysis and Forecast
9.1 Introduction
9.2 North America Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Type
9.6.1 Chemosynthesis Drug
9.6.2 Biological
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Applications
9.10.1 Oncology
9.10.2 Anti-Diabetic
9.10.3 Cardiovascular
9.10.4 Musculoskeletal
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Sterile Dry Powder Active Pharmaceutical Ingredient (API) Analysis and Forecast
10.1 Introduction
10.2 Europe Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Type
10.6.1 Chemosynthesis Drug
10.6.2 Biological
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Applications
10.10.1 Oncology
10.10.2 Anti-Diabetic
10.10.3 Cardiovascular
10.10.4 Musculoskeletal
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Sterile Dry Powder Active Pharmaceutical Ingredient (API) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Type
11.6.1 Chemosynthesis Drug
11.6.2 Biological
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Applications
11.10.1 Oncology
11.10.2 Anti-Diabetic
11.10.3 Cardiovascular
11.10.4 Musculoskeletal
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Sterile Dry Powder Active Pharmaceutical Ingredient (API) Analysis and Forecast
12.1 Introduction
12.2 Latin America Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Type
12.6.1 Chemosynthesis Drug
12.6.2 Biological
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Applications
12.10.1 Oncology
12.10.2 Anti-Diabetic
12.10.3 Cardiovascular
12.10.4 Musculoskeletal
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Sterile Dry Powder Active Pharmaceutical Ingredient (API) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Type
13.6.1 Chemosynthesis Drug
13.6.2 Biological
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size Forecast by Applications
13.10.1 Oncology
13.10.2 Anti-Diabetic
13.10.3 Cardiovascular
13.10.4 Musculoskeletal
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market: Competitive Dashboard
14.2 Global Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Dr. Reddy's Laboratories
14.3.2 Lonza Group
14.3.3 Sandoz International GmbH
14.3.4 Pfizer, Inc.
14.3.5 Aurobindo Pharma Limited
14.3.6 Corden Pharma GmbH
14.3.7 Sun Pharmaceutical Industries Ltd
14.3.8 Sanofi SA
14.3.9 Dalton Pharma Services
14.3.10 Teva Pharmaceutical Industries Ltd
14.3.11 Dr. Reddy's Laboratories
